Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
drug approvals
Biotech
The FDA's decision on aducanumab will drag down science
The amyloid theory just won’t die. In fact, by approving Biogen's new Alzheimer's drug, the FDA has resurrected it for a long and healthy future.
Ben Adams
Jun 9, 2021 8:45am
Aducanumab approval appears to boost Biogen's AD competitors
Jun 7, 2021 1:00pm
New drug approvals hit a high note in 2020 but face uncertainty
Jan 4, 2021 6:00am
New commish, COVID-19, bad comms hitting FDA speedy approvals
Aug 26, 2020 8:40am
EMA starts accelerated review of Gilead's remdesivir
May 1, 2020 6:00am
Giuliani-promoted COVID-19 therapy nabs FDA speedy start
Apr 2, 2020 9:00am